Physician profile
Adwait Silwal
NPI 1114181419
$1,200.45
in general payments reported to CMS, 2019-2025
13 companies · $169 in 2025
The $169 reported for 2025 was less than what a typical Infectious Disease provider received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $169 · 2021: $130 · 2022: $245 · 2023: $411 · 2024: $76.22 · 2025: $169.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $632 · Education: $24.61.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $632.04 |
| Education | $24.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $419.89 | 2021-2025 | Dovato, Cabenuva, Apretude |
| Insmed, INC. | $146.30 | 2022-2025 | Arikayce |
| Gilead Sciences, INC. | $127.86 | 2021-2023 | |
| Astellas Pharma US INC | $99.00 | 2019 | |
| Abbvie INC. | $86.68 | 2023-2024 | Dalvance, Avycaz |
| Merck Sharp & Dohme LLC | $82.88 | 2023-2025 | Zerbaxa, Dificid, Recarbrio |
| Janssen Products, Lp | $69.99 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $42.03 | 2021-2023 | Hyqvia |
| Paratek Pharmaceuticals, INC. | $34.30 | 2022-2023 | Nuzyra |
| Aimmune Therapeutics, INC. | $25.71 | 2025 | Zenpep |
| Ferring Pharmaceuticals INC. | $24.61 | 2023 | Rebyota |
| Pfizer INC. | $23.90 | 2023 | |
| Janssen Biotech, INC. | $17.30 | 2023 | Symtuza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adwait Silwal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.